Peter Hokland

  1. EVOLUTION OF SUBCLONAL LEUKEMIC POPULATIONS DURING AND AFTER THERAPY IN MDS AND AML

    Simonsen, A. T., Ommen, H. B., Nyvold, C. G., Nederby, L. & Hokland, P.

    01/12/201412/04/2019

    Projekter: ProjektForskning

  2. Detecting minimal residual disease in qPCR negative CML patients: is pre-selection by FACS sorting the solution?

    Hokland, P., van Kooten Niekerk, P. B., Nyvold, C. G. & Kjeldsen, E.

    01/11/201230/06/2013

    Projekter: ProjektForskning

  3. The content of aldehyde dehydrogenase enzyme as a marker for myeloid stem cells

    Hokland, P., Jeyaratnam, D. C., Roug, A. S. & Toft-Petersen, M.

    01/09/201230/09/2014

    Projekter: ProjektForskning

  4. Minimal residual disease in AML patients carrying 11q23 related mutations

    Hokland, P., Ommen, H. B. & Schnittger, S.

    01/05/201231/05/2013

    Projekter: ProjektForskning

  5. Inheritance or environment? Premalignant mutations in hematopoietic stem cells in identical twins

    Hokland, P., Nyvold, C. G., Roug, A. S. & Nederby, L.

    01/03/201230/09/2013

    Projekter: ProjektForskning

  6. The hMICL C-type Lectin in early hematopoiesis

    Hokland, P., Roug, A. S., Nederby, L. & Bjerre, L.

    01/01/201101/09/2015

    Projekter: ProjektForskning

  7. The myeloid leukemic stem cell

    Hokland, P., Roug, A. S., Bjerre, L. & Nederby, L.

    01/01/201131/12/2014

    Projekter: ProjektForskning

  8. When and how to stop tyrosine kinase therapy in CML patients in remission - an approach to the myeloid stem cell

    Hokland, P., van Kooten Niekerk, P. B., Roug, A. S. & Nederby, L.

    01/09/201030/09/2014

    Projekter: ProjektForskning